The National Pharmaceutical Pricing Authority (NPPA) on March 25, 2026, has revised the ceiling prices of specified scheduled formulation packs, including Meropenem injections, under the Drugs (Prices Control) Order, 2013, superseding the earlier order dated August 29, 2025. The revised prices are exclusive of GST and will be effective from April 1, 2026, incorporating a WPI increase of 0.64956% for 2025 over 2024.
Manufacturers selling formulations above the notified ceiling prices must reduce prices accordingly, while those with lower MRPs may revise prices upward within the WPI limit. Any manufacturer seeking a separate ceiling price for special dual-chamber bag variants must apply to NPPA for approval. GST may be added only if actually payable.
The notification also mandates strict compliance and reporting, including submission of price revisions (Form-II), issuance of price lists (Form-V), and quarterly returns (Form-III). Non-compliance or overcharging will attract recovery with interest under DPCO, 2013 read with the Essential Commodities Act, 1955, and all previous related price orders stand superseded.
[Notification No. S.O. 1589(E)]
